The latest biotech news

News and Trends 2 May 2023

Astellas eyes ophthalmology field with $5.9B Iveric Bio takeover

Astellas Pharma Inc., through Berry Merger Sub, Inc., a wholly-owned subsidiary of Astellas US Holding, Inc., has agreed to acquire 100% of the outstanding shares of Iveric Bio, Inc., for $40 per share in cash for a total equity value of approximately U.S. $5.9 billion. Iveric Bio will become an indirectly wholly-owned subsidiary of Astellas. […]

May 2, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 2 May 2023

Schizophrenia injection gets FDA approval

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., and MedinCell have announced the U.S. Food and Drug Administration (FDA) has approved UZEDY (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults. UZEDY is the first subcutaneous, long-acting formulation of risperidone that utilizes SteadyTeq, a copolymer technology proprietary to MedinCell that controls […]

May 2, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 2 May 2023

Single-molecule valve breakthrough could lead to early disease diagnosis

Molecules are incredibly small – around one hundred millionth the size of a softball – and they move randomly in liquids, making it difficult to manipulate them in a single form. To overcome this challenge, “nanofluidic devices” that can transport molecules in extremely narrow channels, similar in size to one millionth of a straw, are […]

May 2, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 28 Apr 2023

Brenus Pharma reveals ‘groundbreaking’ preclinical results for colorectal cancer and solid tumor drug

Brenus Pharma has announced what it said are two groundbreaking presentations on STC-1010, the company’s first drug candidate for colorectal cancer (CRC), produced by Brenus Pharma’s STC (stimulated tumor-cells) technology platform. Innovative models for anti-tumor vaccine development were highlighted: Inovotion’s CAM (chorioallantoic model) in-ovo assay and Explicyte’s ex-vivo co-cultured assay, were used to characterize the […]

April 28, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 28 Apr 2023

Mezzion Pharma raises $40M for treatment option for heart surgery patients

Mezzion Pharma, a rare disease focused pharmaceutical company, has secured nearly $40 million to fund FUEL-2, its confirmatory phase 3 clinical trial, along with future commercialization and regulatory submissions in other countries including Europe. Mezzion Pharma is looking to bring to market JURVIGO (udenafil), a highly selective, unique and potent phosphodiesterase type 5 (PDE-5) inhibitor, […]

April 28, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 28 Apr 2023

Vitalli Bio formed to focus on immunological disorders

Aditum Bio has announced the formation of Vitalli Bio, a portfolio company created for the development of novel therapies for immunological disorders. Aditum Bio is a biotech investment firm cofounded in 2019 by former Novartis CEO Joe Jimenez and former president of the Novartis Institutes for BioMedical Research (NIBR) Mark Fishman. Vitalli Bio is being […]

April 28, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 28 Apr 2023

ADC firm Adcentrx Therapeutics aims for clinic after $38M boost

Antibody-drug conjugate (ADC) biotech company Adcentrx Therapeutics has closed a $38 million Series A+ financing. The round was led by Eight Roads Ventures, with participation from F-Prime Capital, ABio-X, Delta Capital, Trinity Innovation Fund, and other strategic investors. Life Venture Partners and Lighthouse Capital acted as Adcentrx’s financial advisors. Adcentrx Therapeutics intends to use the […]

April 28, 2023 - 2 minutesmins - By Jim Cornall

News and Trends 27 Apr 2023

Australian biopharma Telix banks on AI with Dedicaid acquisition

Australian biopharma company Telix Pharmaceuticals Limited is expanding its artificial intelligence (AI) capability with the signing of an agreement to acquire Austria-based Dedicaid GmbH, a spin-off of the Medical University Vienna. Dedicaid’s core asset is a clinical decision support software (CDSS) AI platform capable of rapidly generating indication-specific CDSS applications from available datasets, for use […]

April 27, 2023 - 4 minutesmins - By Jim Cornall

News and Trends 27 Apr 2023

Vedanta Biosciences raises $106.5M for microbiome therapy

Vedanta Biosciences, a clinical-stage company developing a potential new category of oral therapies based on defined bacterial consortia, has raised $106.5 million. The funds will support pivotal-stage development of the U.S. company’s lead candidate, VE303, for the prevention of recurrent Clostridioides difficile infection (CDI), and a phase 2 study of VE202 for ulcerative colitis, among […]

April 27, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 27 Apr 2023

Patients with asthma and other inflammatory lung diseases can be treated ‘in a fundamentally new way’

Arrowhead Pharmaceuticals Inc. has announced interim results from an ongoing phase 1/2 clinical study of ARO-RAGE, an investigational RNA interference (RNAi) therapeutic designed to reduce production of the receptor for advanced glycation end products (RAGE) as a potential treatment for inflammatory pulmonary diseases, such as asthma. These data represent the first clinical demonstration of the […]

April 27, 2023 - 3 minutesmins - By Jim Cornall

News and Trends 27 Apr 2023

Biogen ALS drug gets FDA ok

The U.S. Food and Drug Administration (FDA) has approved Biogen’s QALSODY (tofersen) 100 mg/15mL injection for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. This indication is approved under accelerated approval based on reduction in plasma neurofilament light chain (NfL) observed in patients […]

April 27, 2023 - 5 minutesmins - By Jim Cornall

News and Trends 26 Apr 2023

LincRNA discovery could lead to targeted treatments

Our genetic code includes more than 15,000 specific sections that can be made into molecules called lincRNAs. Some of these sections can occur in coiled-up sections of our genome called topologically associating domains, or TADs. LincRNAs derived from TADs appear to act as markers indicating the specific kind of tissue they are within. When something […]

April 26, 2023 - 3 minutesmins - By Jim Cornall

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Astellas eyes ophthalmology field with $5.9B Iveric Bio takeover

Schizophrenia injection gets FDA approval

Single-molecule valve breakthrough could lead to early disease diagnosis

Brenus Pharma reveals ‘groundbreaking’ preclinical results for colorectal cancer and solid tumor drug

Mezzion Pharma raises $40M for treatment option for heart surgery patients

Vitalli Bio formed to focus on immunological disorders

ADC firm Adcentrx Therapeutics aims for clinic after $38M boost

Australian biopharma Telix banks on AI with Dedicaid acquisition

Vedanta Biosciences raises $106.5M for microbiome therapy

Patients with asthma and other inflammatory lung diseases can be treated ‘in a fundamentally new way’

Biogen ALS drug gets FDA ok

LincRNA discovery could lead to targeted treatments

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!